Several regulatory guidances on the use of physiologically based pharmacokinetic (PBPK)
analyses and physiologically based biopharmaceutics model (s)(PBBM (s)) have been …

When mycophenolic acid (MPA) was originally marketed for immunosuppressive therapy,
fixed doses were recommended by the manufacturer. Awareness of the potential for a more …

The burden of patent ductus arteriosus (PDA) continues to be significant. In view of marked
differences in preterm infants versus more mature, term counterparts (viewed on a …

Posaconazole is typically used for preventing invasive yeast and mold infections such as
invasive aspergillosis in high-risk immunocompromised patients. The oral suspension was …

Early human life is considered a critical window of susceptibility to external exposures.
Infants are exposed to a multitude of environmental factors, collectively referred to as the …

Drug-drug interactions (DDIs) arising from the perturbation of drug metabolising enzyme
activities represent both a clinical problem and a potential economic loss for the …

Enzymes of the UDP-glucuronosyltransferase (UGT) superfamily contribute to the
elimination of drugs from almost all therapeutic classes. Awareness of the importance of …

The Fusarium mycotoxin deoxynivalenol (DON) and its modified forms are present in most
samples of grain and grain-based products. Due to the widespread presence of DON in …

Capturing ontogeny of enzymes involved in phase I metabolism is crucial to improve
prediction of dose‐concentration and concentration‐effect relationships throughout infancy …

Cannabidiol (CBD) is approved for treatment of seizures associated with two forms of
epilepsy that become apparent in infancy or early childhood. To consider an adult …